Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic impact of EGFR-mutated non-small-cell lung cancer on families
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of EGFR-mutated non-small-cell lung cancer

Economic impact of EGFR-mutated non-small-cell lung cancer on families

1 evidence topic · 1 source

Broader NSCLC evidence: reduced caregiver working hours

“NSCLC and BC caregivers worked 61% and 68%, respectively, of the hours relative to prediagnosis” (opens the source at this quote in a new tab)